Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) have recently
entered the therapeutic armamentarium of clinical oncologists, and show promising activity …

Pharmacological inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are now an
established standard of care for patients with advanced hormone receptor-positive breast …

Using transgenic mouse models, cell line-based functional studies, and clinical specimens,
we show that cyclin D1/CDK4 mediate resistance to targeted therapy for HER2-positive …

Cancer proliferation and progression involves altered metabolic pathways as a result of
continuous demand for energy and nutrients. In the last years, cell cycle regulators have …

Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer
and is a biomarker of cancer phenotype and disease progression. The ability of these …

TSC1 and TSC2 are the tumour-suppressor genes mutated in the tumour syndrome TSC
(tuberous sclerosis complex). Their gene products form a complex that has become the …

In contrast to its close homolog CDK4, the cell cycle kinase CDK6 is expressed at high
levels in lymphoid malignancies. In a model for p185 BCR-ABL+ B-acute lymphoid …

Purpose We investigated the global gene expression in a large panel of pancreatic
endocrine tumors (PETs) aimed at identifying new potential targets for therapy and …

Cell growth is coupled to cell-cycle progression in mitotically proliferating mammalian cells,
but the underlying molecular mechanisms are not well understood. CyclinD-Cdk4/6 is …